Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.68 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.68 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.68 |
| ▸ | MMP3 | P08254 | 1/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL40834 | 1.00 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL40836 | 1.00 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL1200549 | 1.00 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL8709954 | 1.00 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL29151798 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL497165 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL497163 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL229272 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL8709949 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 | |
| Doxycycline Anhydrous SCHEMBL17747966 | 0.99 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119607009-A | Application of radix tetrastigme polysaccharide combined anthracycline compound in preparation of triple negative breast cancer treatment drugs | 浙江中医药大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-116327708-B | Method for preparing nano-particles and method for preparing nano-drug-carrying particles | 西南交通大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-118415987-A | Baicalin liposome and preparation method and application thereof | 齐鲁工业大学(山东省科学院) | 2024-08-02 | — | — | CN | disclosed |
| CN-115970658-A | Preparation method and application of zero-valent iron-based covalent organic framework composite material | 西华师范大学 | 2023-04-18 | — | — | CN | disclosed |
| EP-4057814-A1 | ANTIMICROBIAL AND ANTIVIRAL, BIOLOGICALLY ACTIVE POLYMER COMPOSITES EFFECTIVE AGAINST SARS-COV-2 AND OTHER VIRAL, BACTERIAL AND FUNGAL TARGETS, AND RELATED METHODS, MATERIALS, COATINGS AND DEVICES | Iasis Molecular Sciences, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |